Pancreatic cancer is one of the most lethal cancers and has a global survival rate of less than 5% at 5 years. Surgical resection remains the only curative measure but provides a median survival of only 12-15 months, due to the very high rates of both local recurrence and distant metastases. On the basis of this natural history, multiple adjuvant and more recently neoadjuvant therapies have been investigated in order to improve survival. This review is a critical assessment of the results and limitations of such trials and the authors discuss a rationale for the introduction of new developments in the (neo)adjuvant setting of pancreatic cancer.

### Postoperative adjuvant therapy

The number of large randomised trials remains relatively limited. The trials respectively conducted by the Gastrointestinal Tract cancer Study Group (GITSG) and the EORTC (40891) evaluated the addition of external-beam radiation therapy (EBRT) and concomitant 5FU as radiosensitizer after surgical resection (Table I). In both trials, radiation consisted of 40 Gy given as a split course and 5FU given during weeks 1 and 5. The GITSG trial demonstrated a survival advantage for this multimodal therapy compared to resection alone (20 vs 11 months) but only included 43 patients. Ever since, adjuvant chemoradiation with 5FU as radiosensitizer has been considered in the US as standard of care after curative surgery.

Between 1987 and 1995, 218 patients were randomized in the EORTC trial to receive either surgery followed by chemoradiation (40 Gy in a split course + a 5FU infusion during 2x5 days) or no further treatment after surgery. Of these, 114 patients had pancreatic head cancer and the rest have periampullary tumors. The subgroup of pancreatic cancer patients who had multimodal treatment displayed a trend towards longer median survival than those who had surgery alone (17 vs 12.6 months) but the study was not sufficiently powered to demonstrate a statistically significant benefit. Consequently, this adjuvant regimen was not considered as a standard treatment and, in Europe, surgery alone remains the standard care.

In a Norwegian study, the role of AMF (Adriamycin, Mitomycin and 5FU) chemotherapy was investigated in the adjuvant setting; this study enrolled 61 patients and showed a significant prolongation of median survival but no difference at 5 years.

All these trials raised challenging questions regarding either the methodology or the treatment regimen used:

- 20 to 24% of the assessable patients did not receive the intended treatment because of patient refusal, prolonged recovery after Whipple’s resection or rapid tumour progression, thus introducing a bias into the results;
- no stratification was made between pancreatic and periampullary tumors which were mixed up at enrolment;
- the retroperitoneal margins were not accurately determined;
- compared to continuous radiation and 5FU administration, the treatment regimens, comprising split course radiation and 5 FU bolus, cannot be considered optimal;
- there was no quality control/standardization of surgery and radiotherapy.

Details were recently published of the ESPAC-1 trial, the largest trial so far conducted in the setting of adjuvant therapy for pancreatic cancer; this trial assessed the relative ro-
of chemotherapy (bolus 5FU + folinic acid, 5 days monthly), chemoradiation (2x20 Gy over 2 weeks with bolus 5FU) or chemoradiation followed by chemotherapy versus surgery alone in 541 patients (Table I). This trial, however, was submitted to multiple criticisms for its study design, interpretation of data and control of the quality of the resources used; thus, the 541 eligible patients from 51 different centers were randomized in different ways, in order to increase the accrual in a pragmatic fashion: 285 were included in a two-by-two factorial design (70 for chemoradiation, 74 for chemotherapy, 72 for both, and 69 for observation only); another 68 patients were randomly assigned to chemoradiation or non chemoradiation and 188 to chemotherapy or no chemotherapy.

Results emerging from the two-by-two factorial analysis (n = 285) did not show longer survival for patients treated with chemotherapy or chemoradiation compared to observation. By contrast, when pooling the results for all the patients included in the different randomization options in a somewhat peculiar way, the authors showed evidence of a survival benefit after adjuvant chemotherapy (median survival: 19.5 months for the 238 patients with chemotherapy vs 14.0 months for the 235 patients without, p < 0.0005). On the other hand, there was no difference between the median survival of the 175 patients receiving chemoradiation vs the 178 patients without chemoradiation (15.5 vs 16.1 months, p = 0.024) (Table I). Major prognostic factors were involvement of the resection margin, tumour grade, tumour size, nodal involvement and administration of chemotherapy.

Should these conclusions affect our view of the role of chemoradiation after surgery for pancreatic cancer? As raised by the accompanying editorial, this study triggered a great deal of criticisms and is subject to all the methodological pitfalls outlined above.

Moreover, because of serious concerns that enough patients might not be available for the 2x2 randomization in this trial, the investigators pragmatically added two additional ways of randomization: chemotherapy vs no chemotherapy and chemoradiation vs no chemoradiation; they also allowed patients to receive, according to their own or their physician's preference additional "background" chemotherapy or chemoradiation that were not part of the study regimens. Subsequently, the results emerged in three parallel trials in which a high proportion of patients (about 40%) received therapies that were not defined when the study started. All these modifications undoubtedly led to odd classifications in which "no chemotherapy" patients who had received chemoradiation were compared to "chemotherapy" patients who also had received chemoradiation. The same criticism held true for the "chemoradiation" and "no chemoradiation" groups. In addition, the inclusion criteria were inconclusive for the different groups mentioned. Therefore it might be conceivable that, due to the interactions of the different therapies, the study is underpowered and does not allow a proper comparison of the relative regimens.

Consequently, it seems not possible to draw any definite conclusion from the results of the ESPAC-1 trial as regards the efficacy of chemoradiation, which was used in a suboptimal regimen, in the adjuvant setting of pancreatic cancer. In addition, recommendation of 5FU/folinic acid regimens, which has displayed extremely low activity in metastatic pancreatic cancer, is also not justified after curative resection as it is unlikely that a treatment that has virtually no activity in advanced disease is active in the adjuvant setting.

Neoadjuvant therapy

The risk of delaying or not receiving postoperative adjuvant treatment prompted many investigators to initiate studies in which chemoradiation using 5FU as a radiosensitizer was given before surgery (Table II). There might be theoretically
some tumor-biological advantages of preoperative chemoradiation especially based on short and intensive course of radiotherapy, but so far, the only reports regarding the acceptability and feasibility of such therapy concern small non-randomized series. Therefore, most surgeons remain reluctant into using this approach and prefer the post-operative treatment. The potential advantages of preoperative chemoradiation are:

– 1 increased cell sensitivity to radiation before surgery due to better oxygenation of the tumor cells
– 2 no delay of postoperative recovery and postponement of the planned treatment
– 3 lower incidence of postoperative anastomotic leaks
– 4 lower rate of positive margin resection (retroperitoneal) due to downstaging
– 5 avoidance of surgery in patients with evidence of rapidly disseminating disease on restaging after chemoradiation (25%) and thus better selection of patients who will benefit from pancreatic resection.

Several phase II studies have been published. They have shown the feasibility of combining preoperatively radiation (30 to 50 Gy) and continuous 5FU infusion (300 mg/m²/day)13-15. In one study, toxicity was reduced when chemoradiation was delivered over 2 weeks up to a total dose of 30 Gy (3 Gy/fraction); 20/35 patients underwent successful pancreaticoduodenectomy. Local tumour control and patient survival were equal to the results provided by standard fractionated chemoradiation (50.4 Gy in 5.5 weeks, 1.8 Gy/fraction); only 10% of the 20 patients resected had a loco-regional relapse and the median survival for all 20 was 25 months15 (Table II). Another non-randomised study reported on the survival advantage of preoperative chemoradiation in patients with regional pancreatic cancer; a first group of 68 patients with proven unresectable pancreatic cancer was given radiation (40 Gy in split course) combined with 5FU, platinum and streptozocin and 20 of them were then curatively resected; another group of 91 patients with resectable pancreatic cancer underwent surgery first followed by chemotherapy ± radiation in 63 of them. Median survival was 23.6 months in the neoadjuvant group compared to 14 for the patients with initial resectable disease (p=0.006) while the postoperative mortality rates were similar (0 and 5%, respectively)16. Although these data were based on a historical control group, they suggest that control of the disease can be improved by downsizing the tumour through neoadjuvant therapy. On the other hand, it should be taken into account that the survival gain emerging from these neoadjuvant studies may simply result from better selection of patients: firstly, preoperatively, by accurate staging and secondly, postoperatively when only the good responders benefited from curative resection.

As toxicity emerging from this approach is moreover not negligible, it certainly needs further refinement and more data on feasibility before embarking into large randomized trials. Also, the elaboration of neoadjuvant strategies for combined modality treatments calls for the following requirements:

• a proper definition of inclusion criteria
• a proven pancreatic adenocarcinoma (by histology or cytology)
• an accurate definition of resectability of the tumor by a surgical team
• an optimal biliary drainage to avoid morbidity due to cholangitis during chemoradiation.
• Consequently, this strategy should therefore be restricted to clinical trials.

New combined regimens

Although the modalities of 5FU-based chemoradiation can be further explored (neoadjuvant setting, intensified regimen, continuous infusion for the entire chemoradiation period of 6 weeks), we clearly need more innovative drug regimens in view of the limited activity of 5FU in metastatic pancreatic cancer11, 12. This is needed in order to achieve, not only a better locoregional tumor control, by maximizing additive or synergistic effects with radiation, but also to treat microscopic extrapancreatic metastatic disease which is responsible of most tumour relapses.

Gemcitabine, a deoxycytidine analogue capable of inhibiting DNA replication and repair, has proved more beneficial than 5FU in advanced pancreatic cancer, with a higher response rate (5.4 vs 0%), greater clinical benefit (23.8 vs 4.8%) and longer survival (5.65 vs 4.41 months)17. Gemcitabine is also a potent radiosensitizer of human pancreatic cells in vitro (PANC-1) and in vivo models18, 20.
There is now increasing clinical evidence that gemcitabine administration can be combined with radiation in pancreatic cancer, both in locally advanced disease and in the setting of (neo)adjuvant treatment; the most important phase I and II studies reported so far are shown in Table III. Gemcitabine was mainly administered weekly (300 to 500 mg/m² infused over 30 min IV) or twice weekly (40 mg/m² X2) with concomitant radiation (30 to 50.4 Gy) 21-33. Other approaches included giving gemcitabine at a fixed dose of 1000 mg/m² while increasing the intensity of the weekly dose of radiation34. The overall treatment time was kept constant at 3 weeks (15 fractions of radiation) and the total dose was increased from 24 Gy to 42 Gy. The authors recommend 36 Gy in 2.4 Gy fractions on the basis of tolerance, patterns of failure and survival data. All these regimens exhibited good feasibility and acceptable, although not negligible toxicity. So far, approximately 10 phase I-II studies including a median of 17 patients (range: 8-58) have been reported, with a rate of grade 4 toxicity (mainly hematological and gastrointestinal) in less than 20-25% of the patients, compliance with the treatment of about 80% and no major late reactions observed after a follow-up period of 12 to 17 months26, 28, 31, 32. The results were quite promising, as complete and partial responses were observed both in locally advanced disease and in the neoadjuvant setting. Feasibility of gemcitabine combined with radiation therapy in the neoadjuvant setting was recently reported in a large series of 86 patients30. Although manageable, the hospitalization rate related to the toxicity of this regimen was high (43%) and underlines the fact that this kind of approach should be unequivocally restricted to appropriate trials. High toxicity rates could be attributed to the rapid-fractionated radiotherapeutic scheme (3 Gy/fraction) as well as the risk of cholangitis in patients with endobiliary stenting. The activity of such a combination with high pathological response rate is appearing. However a survival benefit has not yet been demonstrated.

Gemcitabine based chemoradiation was also successfully administered in the postoperative adjuvant setting in two reports, showing a good tolerance and no major toxicities 30, 31. In addition to our first study, an intensified post operative combined regimen was recently assessed using weekly gem-

<table>
<thead>
<tr>
<th>Author (year) (reference)</th>
<th>No of patients</th>
<th>Gemcitabine mg/m²/week</th>
<th>RT</th>
<th>Toxicity (gr 3-4) (nb patients)</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Locally advanced disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mc Ginn (1998) 13 (21)</td>
<td>13</td>
<td>200-400</td>
<td>50.4 Gy</td>
<td>GI</td>
<td>–</td>
</tr>
<tr>
<td>Kudrimati (1999) 18 (22)</td>
<td>18</td>
<td>50-150 (24h inf)</td>
<td>40 Gy</td>
<td>GI (10)</td>
<td>5 CR</td>
</tr>
<tr>
<td>Reyes-Vidal (2000) 14 (23)</td>
<td>14</td>
<td>200-325</td>
<td>45 Gy</td>
<td>respiratory (1)</td>
<td>2 CR</td>
</tr>
<tr>
<td>Epelbaum (2002) 20 (24)</td>
<td>20</td>
<td>400</td>
<td>50.4 Gy</td>
<td>GI (5)</td>
<td>4 PR</td>
</tr>
<tr>
<td>Mustacchi (2001) 15 (25)</td>
<td>15</td>
<td>500</td>
<td>45.5 Gy</td>
<td>GI (9)</td>
<td>6 SD</td>
</tr>
<tr>
<td>Blackstock (2001) 38 (26,27)</td>
<td>38</td>
<td>2x40</td>
<td>50.4 Gy</td>
<td>GI 4 hemato (6)</td>
<td>–</td>
</tr>
<tr>
<td>Preoperatively</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wolff (1998) 9 (28)</td>
<td>9</td>
<td>400</td>
<td>30 Gy</td>
<td>Gr 3 neutro (4)</td>
<td>2 PR</td>
</tr>
<tr>
<td>Hoffman (1998) 18 (29)</td>
<td>18</td>
<td>300-500</td>
<td>50.4 Gy</td>
<td>Gr 3 hemato (4) cholangitis (9)</td>
<td>4 PR</td>
</tr>
<tr>
<td>Wolff (2002) 86 (30)</td>
<td>86</td>
<td>400</td>
<td>30 Gy</td>
<td>Hospitalization rate 43%</td>
<td>2 CR PR : 59%</td>
</tr>
<tr>
<td>Postoperatively</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van Laethem (2003) 17 (31)</td>
<td>17</td>
<td>300</td>
<td>40 Gy split</td>
<td>GI (1)</td>
<td>–</td>
</tr>
<tr>
<td>Kachnic (2001) 15 (9)</td>
<td>15 (9)</td>
<td>2x40</td>
<td>50.4 Gy</td>
<td>Gr 3 hemato (3)</td>
<td>–</td>
</tr>
<tr>
<td>Demols (2003) 30 (33)</td>
<td>30</td>
<td>300</td>
<td>45 Gy</td>
<td>GI : 30% Hemato : 32%</td>
<td>–</td>
</tr>
</tbody>
</table>

CR: complete response, PR: partial response, SD: stable disease; GI: gastrointestinal; neutro: neutropenia; hemato: hematological; Gr: grade
citabine (300 mg/m²) with 45 Gy continuous radiation. In 28/30 patients, tolerance and compliance of treatment were quite good and toxicity acceptable.

A recent study compared the therapeutic index of gemcitabine-based chemoradiation to that of 5FU-based chemoradiation in patients with locally advanced disease. Although it was retrospective, it clearly emphasized that, for comparable patients receiving similar radiation regimen (30 Gy in 10 fractions), severe acute toxicity was significantly higher in the group of patients treated with gemcitabine compared to 5FU (23% vs 2%, p< 0.0001) while recurrence rate and survival were comparable. However, a small number of patients with minimal arterial involvement whose disease met the radiographic definition of unresectable disease had margin-negative resections after treatment with gemcitabine-based chemoradiation. Therefore, some selected patients could probably benefit from a such neoadjuvant approach inside clinical trials.

Based on the previously reported data, it seems warranted to use gemcitabine in the adjuvant setting of pancreatic cancer, as this agent may help to control both micrometastatic dissemination and local recurrence when combined with concomitant radiation. However, the above mentioned data suggest that the therapeutic ratio for this type of combination may be significant. It should also be noted that an extremal level of patients selection has gone into these pilot trials; therefore these combinational regimens are not yet suitable for general use and should be further and more widely evaluated in prospective phase II trials.

Other new agents that will be assessed more deeply in the near future include paclitaxel which has revealed promising activity as a radiosensitizer (response rates of 26-29% in locally advanced disease) and limited toxicity in preliminary reports. Other drugs like cisplatin, oxaliplatin or biological agents targeted to the Epidermal Growth Factor receptor or Her-neu2 receptor in combination or not with radiation.

### Perspectives in the adjuvant setting

Previous trials have led to conflicting or underpowered results. The results of large but retrospective and non-randomized single institution experiences, or of randomized, but small trials like those conducted by the GITSG or the EORTC suggest that adjuvant chemoradiation may be beneficial, although the EORTC trial was probably an underpowered positive trial rather than a negative one as mentioned above.

On the other hand, investigators involved in the large ESPAC-1 trial reported a survival benefit for 5FU-based chemoradiation only, while they claimed that chemoradiation has a confounding negative effect on the benefit of chemotherapy alone; the criticisms concerning this study have been outlined above and the conclusions drawn from this trial should likely not change our standard practice.

What are the major directions that we have to follow for the creation of new trials in the adjuvant setting? Neoadjuvant strategies seem clearly attractive, mainly to test the tolerance and the activity profile of new compounds within the frame of clinical phase II trials. These should also include targeted therapies after identification of, e.g., Epidermal or Vascular-endothelial growth factor receptors. Today, it is probably too early to propose a large randomized trial taking into account the possible difficulties to manage such patients preoperatively.

Addressing the postoperative approach, there are still controversies on the definition of the standard treatment for resectable pancreatic cancer. In the US, 5FU-based chemoradiation has been considered standard of care, since the reports of the GITSG trial and the 5FU-based chemoradiation experience. This strategy has been incorporated into both arms of the current RTOG phase III trial (Table IV). The question raised by this trial is important: can the addition of gemcitabine-based chemotherapy to chemoradiation increase the median survival from 18 months to 25 months as compared to the control arm?

### Table IV

Ongoing trials in the adjuvant setting of pancreatic cancer

<table>
<thead>
<tr>
<th>TRIAL</th>
<th>Treatment arms</th>
<th>n patients</th>
<th>status</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESPAC 3: (phase III)</td>
<td>R</td>
<td>330</td>
<td>ongoing</td>
</tr>
<tr>
<td></td>
<td>Observation</td>
<td>330</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GEM x 6 cycles</td>
<td>330</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5FU/FA bolus x 6 cycles</td>
<td>330</td>
<td></td>
</tr>
<tr>
<td>RTOG 9704 US trial: (phase III)</td>
<td>GEM ( RT + 5FUc ( GEM 2)</td>
<td>59</td>
<td>closed</td>
</tr>
<tr>
<td></td>
<td>5FU ( RT + 5FUc ( 5 FU</td>
<td>259</td>
<td></td>
</tr>
<tr>
<td>EORTC-FFCD: (phase II-III)</td>
<td>GEM x 2 cycles ( RT + GEM 40/270)</td>
<td>40/ 270</td>
<td>April 03</td>
</tr>
<tr>
<td>German trial: (phase III)</td>
<td>Observation</td>
<td>235</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GEM x 6 cycles</td>
<td>235</td>
<td>ongoing</td>
</tr>
</tbody>
</table>

GEM: gemcitabine, RT: radiation = 50.4 Gy in 28 fractions of 1.8 Gy/fraction.
red with a 5FU based chemotherapy; the study is now closed after enrollment of 518 patients and the results of the first data analysis are awaited. In Europe, it is consensually admitted that surgery alone remains the standard of care. As gemcitabine alone is currently the standard treatment of metastatic disease, its impact on survival after curative resection is questionable and two phase III trials are currently in progress. Subsequently to the ESPAC-1 trial, the ESPAC group has now launched the ESPAC-3 trial which aims to randomizing 990 patients in three arms comparing 5FU/folinic acid (Mayo regimen) for 6 months, vs gemcitabine for 6 months vs observation; the purpose of this trial is to strengthen the beneficial role of chemotherapy, since the ESPAC investigators consider that the potential benefit of chemotherapy observed in the ESPAC-1 trial was not clear, because of the apparent negative effect of chemoradiotherapy A randomized German phase III trial aiming to recruit 470 patients is currently exploring the potential beneficial effects of gemcitabine administered alone in an adjuvant setting (Table IV). It is tempting to postulate that a combination of chemotherapy and chemoradiation aimed at controlling both local and distant relapses would be of potential benefit in the adjuvant setting. The combination of gemcitabine with radiation is a good candidate to be tested in this setting and will deserve further evaluation in the next future (Table IV). Initial assessment of a good tolerability profile is crucial based on the preliminary results observed in selected centers (Table III). The results of these trials will be not available for 3 to 5 years. Meanwhile, current and future research is needed to assess the efficacy of new gemcitabine-based drug combinations adding signal transduction-inhibitors or immunotherapeutic agents like this, we will profit for a better understanding of the disease for the sake of our patients.

References


